var data={"title":"Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6340?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Patient drug information&quot;</a> and <a href=\"topic.htm?path=hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4090481\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cyanokit</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12785471\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cyanokit</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180768\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote;</li>\n      <li>\n        Vitamin, Water Soluble</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180735\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cyanide poisoning:</b> IV: <b>Note:</b> If cyanide poisoning is suspected, antidotal therapy must be given immediately. Initial: 5 <b>g</b> as single infusion; may repeat a second 5 <b>g</b> dose depending on the severity of poisoning and clinical response. Maximum cumulative dose: 10 <b>g</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin B<sub>12</sub> deficiency:</b> IM: Initial: 30 mcg once daily for 5 to 10 days; maintenance: 100 to 200 mcg once per month. <b>Note:</b> Larger doses may be required in critically-ill patients or if patient has neurologic disease, an infectious disease, or hyperthyroidism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180754\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin B<sub>12</sub> deficiency:</b> Infants, Children, and Adolescents: IM: 100 mcg once daily for &ge;2 weeks (total dose: 1 to 5 <b>mg</b>); maintenance: 30 to 50 mcg once per month</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cyanide poisoning (off-label use):</b> Limited data available: Infants, Children, and Adolescents: IV, Intraosseous: <b>Note:</b> If cyanide poisoning is suspected, antidotal therapy must be given immediately; Initial: 70 mg/kg (maximum dose: 5,000 mg/dose) as a single infusion; may repeat a second dose of 70 mg/kg (maximum dose: 5,000 mg/dose) depending on the severity of poisoning and clinical response (Mintegi 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180736\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14602218\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14602219\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180723\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 mcg/mL (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyanokit: 5 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180710\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180726\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer 1000 mcg/mL solution IM only</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV, Intraosseous: Cyanokit: Administer initial dose by IV infusion over 15 minutes; if a second dose is needed, administer the second dose over 15 minutes to 2 hours; intraosseous may be used in pediatric patients (Mintegi 2013). Hydroxocobalamin is chemically incompatible with sodium thiosulfate and sodium nitrite and separate IV lines must be used if concomitant administration is desired <b>(the safety and efficacy of coadministration are not established)</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180725\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM injection: Treatment of pernicious anemia; treatment of vitamin B<sub>12</sub> deficiency due to dietary deficiencies or malabsorption diseases, inadequate secretion of intrinsic factor, competition for vitamin B<sub>12</sub> by intestinal parasites/bacteria, or inadequate utilization of B<sub>12</sub> (eg, during neoplastic treatment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV infusion (Cyanokit): Treatment of cyanide poisoning (known or suspected)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180717\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IM injection:</b> Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash (transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea (mild, transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Swelling (feeling of swelling of the entire body)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>IV infusion (Cyanokit):</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Increased blood pressure (18% to 28%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (6% to 33%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema (94% to 100%; may last up to 2 weeks), skin rash (20% to 44%; predominantly acneiform eruption; can appear 7 to 28 days after administration and usually resolves within a few weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (6% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urine discoloration (100%; may last up to 5 weeks after administration)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphocytopenia (8% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Infusion site reaction (6% to 39%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest discomfort, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, memory impairment, restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; Metabolic: Hot flash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distress, diarrhea, dyspepsia, dysphagia, hematochezia, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Allergic reaction (including anaphylaxis)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eye irritation, eye redness, swelling of eye</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dry throat, dyspnea, pharyngeal edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Angioedema</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180728\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Hypersensitivity to hydroxocobalamin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV (Cyanokit&reg;): There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180714\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertension: Cyanide poisoning: Increased blood pressure (&ge;180 mm Hg systolic or &ge;110 mm Hg diastolic) may occur with infusion; elevations usually noted at the beginning of the infusion, peak toward the end of the infusion, and return to baseline within 4 hours following the end of the infusion. May offset hypotension induced by nitrite administration or cyanide.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Photosensitivity: May cause photosensitivity; avoid direct sunlight while skin remains discolored.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anemia: Appropriate use: Neurologic manifestations of vitamin B<sub>12</sub> deficiency will not be prevented with folic acid unless vitamin B<sub>12</sub> is also given; spinal cord degeneration might also occur when folic acid is used as a substitute for vitamin B<sub>12</sub> in anemia prevention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polycythemia vera: Vitamin B<sub>12</sub> deficiency masks signs of polycythemia vera; vitamin B<sub>12</sub> administration may unmask this condition. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fire victims: Fire victims may present with both cyanide and carbon monoxide poisoning. In this scenario, hydroxocobalamin is the agent of choice for cyanide intoxication since the traditional cyanide antidote that contains sodium nitrite produces methemoglobinemia and may worsen tissue hypoxia. Hydroxocobalamin can discolor the skin and exudates, complicating the assessment of burn severity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cyanokit: Use caution or consider alternatives in patients known to be allergic to, or who have experienced anaphylaxis with hydroxocobalamin or cyanocobalamin. Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of suspected or confirmed cyanide toxicity. Only pretreatment cyanide concentrations may be useful since postinfusion concentrations may be inaccurate. Treatment of cyanide poisoning should include external decontamination and supportive therapy. Use caution with concurrent use of other cyanide antidotes; safety has not been established. Consider consultation with a poison control center at 1-800-222-1222.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Solution for IM injection: Treatment of severe vitamin B<sub>12</sub> megaloblastic anemia may result in thrombocytosis and severe hypokalemia, sometimes fatal, due to intracellular potassium shift upon anemia resolution. Use caution in folic acid deficient megaloblastic anemia; administration of vitamin B<sub>12</sub> alone is not a substitute for folic acid and might mask true diagnosis. Blunted therapeutic response to vitamin B<sub>12</sub> may occur in certain conditions (eg, infection, uremia, concurrent iron or folic acid deficiency) or in patients on medications with bone marrow suppressant properties (eg, chloramphenicol).  Approved for use as IM injection only.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Hydroxocobalamin may interfere with and/or trip alarms in patients who use hemodialysis machines that rely on colorimetric technology.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299483\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180718\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8813&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May diminish the therapeutic effect of Vitamin B12.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180720\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4010117\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal studies are insufficient to determine the effect, if any, on pregnancy or fetal development. There are no adequate and well-controlled studies in pregnant women. Data on the use of hydroxocobalamin in pregnancy for the treatment of cyanide poisoning and cobalamin defects are limited. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570953\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if hydroxocobalamin is excreted in breast milk. Hydroxocobalamin may be administered in life-threatening situations; therefore, use in a breast-feeding woman is not contraindicated. Because of the unknown potential for adverse reactions in nursing infants, the patient should discontinue nursing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3900329\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vitamin B<sub>12</sub>, hematocrit, hemoglobin, reticulocyte count, red blood cell counts, folate and iron levels should be obtained prior to treatment and periodically during treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyanide poisoning: Blood pressure and heart rate during and after infusion, serum lactate levels, venous-arterial PO<sub>2</sub> gradient. Pretreatment cyanide levels may be useful as post infusion levels may be inaccurate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Megaloblastic anemia: In addition to normal hematological parameters, serum potassium and platelet counts should be monitored during therapy, particularly in the first 48 hours of treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180713\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Hydroxocobalamin (vitamin B<sub>12a</sub>) is a precursor to cyanocobalamin (vitamin B<sub>12</sub>). Cyanocobalamin acts as a coenzyme for various metabolic functions, including fat and carbohydrate metabolism and protein synthesis, used in cell replication and hematopoiesis. In the presence of cyanide, each hydroxocobalamin molecule can bind one cyanide ion by displacing it for the hydroxo ligand linked to the trivalent cobalt ion, forming cyanocobalamin, which is then excreted in the urine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4010127\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Following IV administration of Cyanokit&reg;:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Significant; forms various cobalamin-(III) complexes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 26-31 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (50% to 60% within initial 72 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323186\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Hydroxocobalamin Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mcg/mL (30 mL): $38.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cyanokit Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 g (1): $985.58</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539877\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aquo-Cytobion (DE);</li>\n      <li>Articlox (GR);</li>\n      <li>B12 Depot-Rotexmedica (DE);</li>\n      <li>B12-Depot-Hevert (DE);</li>\n      <li>B12-Depot-Vicotrat (DE);</li>\n      <li>Behepan (SE);</li>\n      <li>Benzoral (AR);</li>\n      <li>Berubi-long (DE);</li>\n      <li>Bradirubra (IT);</li>\n      <li>Cobalin-H (AE, GB, MT, QA);</li>\n      <li>Cobalparen (DE);</li>\n      <li>Cobalvit (IT);</li>\n      <li>Cohemin Depot (FI);</li>\n      <li>Cyano Kit (JP);</li>\n      <li>Cyanokit (ES, FR, HR, MT, PL);</li>\n      <li>Cynomin H (BD);</li>\n      <li>Depovit-B 12 (EG);</li>\n      <li>Depovit-B12 (AE, QA);</li>\n      <li>Dodecavit (FR);</li>\n      <li>Doleven (JP);</li>\n      <li>Dosixbe (AR);</li>\n      <li>Douzabin Retard Forte (LB);</li>\n      <li>Forta B 5.000 (BE);</li>\n      <li>Forta B12 (BE, LU);</li>\n      <li>Hepavit (AT);</li>\n      <li>Hycomin (KR);</li>\n      <li>Hydrocobamine (NL);</li>\n      <li>Hydroxo 5.000 (FR, LU);</li>\n      <li>Hydroxo-B 12 (AU);</li>\n      <li>Idroxocobalamina (IT);</li>\n      <li>Lanobin (KR);</li>\n      <li>Lisoneurin (AR);</li>\n      <li>Lophakomp-B 12 Depot (DE);</li>\n      <li>Megamilbedoce (ES);</li>\n      <li>Minedrox (PE);</li>\n      <li>Neo-B12 (AU);</li>\n      <li>Neo-Cytamen (GB, IE, IT, NZ);</li>\n      <li>Novidroxin (DE);</li>\n      <li>Novobedouze (BE, LU);</li>\n      <li>OH B12 (IT);</li>\n      <li>OHB12 (PT);</li>\n      <li>Rasedon 500 (JP);</li>\n      <li>Rubranova (BR);</li>\n      <li>Tarupain (KR);</li>\n      <li>Twelvmin-s (JP);</li>\n      <li>Vibeden (DK);</li>\n      <li>Vitamin B12 Depot (NO);</li>\n      <li>Vitamin B12-Depot-Injektopas (DE);</li>\n      <li>Vitarubin-Depot (CH);</li>\n      <li>Westhidroxo (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Anseeuw K, Delvau N, Burillo-Putze G, et al. Cyanide poisoning by fire smoke inhalation: a European expert consensus. <i>Eur J Emerg Med. </i>2013;20(1):2-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/22828651/pubmed\" target=\"_blank\" id=\"22828651\">22828651</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bebarta VS, Pitotti RL, Borys DJ, et al, &ldquo;Seven Years of Cyanide Ingestions in the USA: Critically Ill Patients are Common, but Antidote Use is Not,&rdquo; <i>Emerg Med J</i>, 2011, 28(2):155-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/20511644/pubmed\" target=\"_blank\" id=\"20511644\">20511644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burnes ML, Boettcher BT, Woehlck HJ, et al. Hydroxocobalamin as a Rescue Treatment for Refractory Vasoplegic Syndrome After Prolonged Cardiopulmonary Bypass. <i>J Cardiothor Vasc Anesth.</i> 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/27838199/pubmed\" target=\"_blank\" id=\"27838199\">27838199</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Curry SC, Connor DA, and Raschke RA, &ldquo;Effect of the Cyanide Antidote Hydroxocobalamin on Commonly Ordered Serum Chemistry Studies,&rdquo; <i>Ann Emerg Med</i>, 1994, 24(1):65-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/8010551/pubmed\" target=\"_blank\" id=\"8010551\">8010551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cyanokit (hydroxocobalamin) [prescribing information]. Columbia, MD: Meridian Medical Technologies Inc; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gracia R and Shepherd G, &quot;Cyanide Poisoning and Its Treatment,&quot; <i>Pharmacotherapy</i>, 2004, 24(10):1358-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/15628833/pubmed\" target=\"_blank\" id=\"15628833\">15628833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hall AH, Dart R, and Bogdan G, &ldquo;Sodium Thiosulfate or Hydroxocobalamin For The Empiric Treatment of Cyanide Poisoning?&rdquo; <i>Ann Emerg Med</i>, 2007, 49(6):806-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/17098327/pubmed\" target=\"_blank\" id=\"17098327\">17098327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huermer M, Simma B, Fowler B, et al, &ldquo;Prenatal and Postnatal Treatment in Cobalamin C Defect,&rdquo; <i>J Pediatr</i>, 2005, 147(4):469-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/16227032/pubmed\" target=\"_blank\" id=\"16227032\">16227032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenbaum J, Healton EB, Savage DG, et al, &ldquo;Neuropsychiatric Disorders Caused by Cobalamin Deficiency in the Absence of Anemia or Macrocytosis,&rdquo; <i>N Engl J Med</i>, 1988, 318(26):1720-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/3374544/pubmed\" target=\"_blank\" id=\"3374544\">3374544</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24196100\"></a>Mintegi S, Clerigue N, Tipo V, et al. Pediatric cyanide poisoning by fire smoke inhalation: a European expert consensus. Toxicology Surveillance System of the Intoxications Working Group of the Spanish Society of Paediatric Emergencies. <i>Pediatr Emerg Care</i>. 2013;29(11):1234-1240.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/24196100/pubmed\" target=\"_blank\" id=\"24196100\">24196100</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nguyen L, Afshari A, Kahn SA, McGrane S, Summitt B. Utility and outcomes of hydroxocobalamin use in smoke inhalation patients. <i>Burns</i>. 2017;43(1):107-113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/27554631/pubmed\" target=\"_blank\" id=\"27554631\">27554631</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olszewski AJ, Szostak WB, Bialkowska M, et al, &ldquo;Reduction of Plasma Lipid and Homocysteine Levels by Pyridoxine, Folate, Cobalamin, Choline, Riboflavin, and Troxerutin in Atherosclerosis,&rdquo; <i>Atherosclerosis</i>, 1989, 75(1):1-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/2930611/pubmed\" target=\"_blank\" id=\"2930611\">2930611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reade MC, Davies SR, Morley PT, et al, &ldquo;Review Article: Management of Cyanide Poisoning,&rdquo; <i>Emerg Med Australas</i>, 2012, 24(3):225-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/22672162/pubmed\" target=\"_blank\" id=\"22672162\">22672162</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1627675\"></a>Regland B, Gottfries CG, and Lindstedt G, &ldquo;Dementia Patients With Low Serum Cobalamin Concentration: Relationship to Atrophic Gastritis,&rdquo; <i>Aging (Milano)</i>, 1992, 4(1):35-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/1627675/pubmed\" target=\"_blank\" id=\"1627675\">1627675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roderique JD, VanDyck K, Holman B, et al. The use of high-dose hydroxocobalamin for vasoplegic syndrome. <i>Ann Thor Surg</i>. 2014;97(5):1785-1786.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/24792267/pubmed\" target=\"_blank\" id=\"24792267\">24792267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sauer SW and Keim ME, &ldquo;Hydroxocobalamin: Improved Public Health Readiness for Cyanide Disasters,&rdquo; <i>Ann Emerg Med</i>, 2001, 37(6):635-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/11385334/pubmed\" target=\"_blank\" id=\"11385334\">11385334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shepherd G and Velez LI, &quot;Role of Hydroxocobalamin in Acute Cyanide Poisoning,&quot; <i>Ann Pharmacother</i>, 2008, 42(5):661-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/18397973/pubmed\" target=\"_blank\" id=\"18397973\">18397973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson JP and Marrs TC, &ldquo;Hydroxocobalamin in Cyanide Poisoning,&rdquo; <i>Clin Toxicol</i>, 2012, 50(10):875-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/23163594/pubmed\" target=\"_blank\" id=\"23163594\">23163594</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong SL, Pudek M, Li D. Wine-Colored Plasma and Urine from Hydroxocobalamin Treatment. <i>J Gen Intern Med.</i> 2016;32(2):225-226.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information/abstract-text/27338592/pubmed\" target=\"_blank\" id=\"27338592\">27338592</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8813 Version 102.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F4090481\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F12785471\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F180768\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F180735\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F180754\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F180736\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14602218\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14602219\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F180723\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F180710\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F180726\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F180725\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F180717\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F180728\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F180714\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299483\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F180718\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F180720\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4010117\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16570953\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3900329\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F180713\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F4010127\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323186\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539877\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8813|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-patient-drug-information\" class=\"drug drug_patient\">Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Patient drug information</a></li><li><a href=\"topic.htm?path=hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information\" class=\"drug drug_pediatric\">Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Pediatric drug information</a></li></ul></div></div>","javascript":null}